Side-by-side comparison of AI visibility scores, market position, and capabilities
Clinical-stage biotech; raised $305M Series F (Jan 2026) for AI-optimized peptides targeting intracellular cancer proteins previously considered undruggable; oncology-first pipeline
Parabilis Medicines is a clinical-stage biotechnology company applying AI to the design of peptide-based therapeutics targeting proteins previously considered undruggable, with a primary focus on oncology. The company was founded on the insight that AI-optimized peptides — short chains of amino acids — can be engineered to reach and modulate intracellular protein targets that small molecules and biologics cannot access. Parabilis uses proprietary computational platforms to design, screen, and optimize peptide candidates with improved cell permeability, stability, and target selectivity.\n\nThe company's pipeline is centered on cancer proteins that drive tumor growth but lack conventional binding pockets for small molecule inhibition. Parabilis's AI-designed peptides are engineered to penetrate cancer cells and disrupt these oncogenic interactions, potentially unlocking entirely new therapeutic options for patients with tumors driven by these targets. The approach also has potential applications in other diseases where intracellular protein-protein interactions are central to pathology.\n\nParabilis raised $305M in a Series F round in January 2026, one of the largest biotech fundraises of that period. The financing was designed to advance its lead programs through clinical development and expand its pipeline of AI-designed peptide candidates. With over $300M in fresh capital, Parabilis is one of the most heavily funded companies in the emerging AI peptide therapeutics space, positioning it to compete with both traditional peptide drug developers and newer AI-native biotech platforms.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.